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Abstract : It has previously been shown by our laboratory that OTK18, a human immunodeficiency virus (HIV)-inducible
zinc-finger protein, reduces progeny-virion production in infected human macrophages. OTK18 antiviral activity is mediated through suppression of Tat-induced HIV-1 long terminal repeat (LTR) promoter activity. Through the use of LTRscanning mutant vectors, the specific regions responsible for OTK18-mediated LTR suppression have been defined. Two
different LTR regions were identified as potential OTK18-binding sites by an enhanced DNA–transcription factor ELISA
system; the negative-regulatory element (NRE) at –255/–238 and the Ets-binding site (EBS) at –150/–139 in the LTR.
In addition, deletion of the EBS in the LTR blocked OTK18-mediated LTR suppression. These data indicate that OTK18
suppresses LTR activity through two distinct regulatory elements. Spontaneous mutations in these regions might enable
HIV-1 to escape from OTK18 antiretroviral activity in human macrophages.

T

he control of human immunodeficiency virus (HIV)
type 1 entry, reverse transcription, integration, expression and production is operated by distinct molecular mechanisms, which have been targeted by antiretroviral therapy.
Among these mechanisms, nuclear factors, such as NF-κB
and 45/39kD CCAAT/enhancer-binding protein-β (C/EBPβ)
isoforms, are important in regulating HIV-1 expression
(Griffin et al., 1989; Henderson et al., 1996). In addition,
several transcription factors can repress virus transcription,
often by binding to specific sequences contained in the virus long terminal repeat (LTR) (Patarca et al., 1988; Subler et al., 1994; Ray & Srinivas, 1997; Weiden et al., 2000;
Cicala et al., 2002; Hayes et al., 2002). Recently, we have
shown that the transcriptional factor OTK18 is induced by
and suppresses HIV-1 infection in mononuclear cells (Carlson et al., 2004a). OTK18 is classified as a transcription
factor as it contains 13 C2H2-type DNA-binding zinc-finger
motifs (Saito et al., 1996). C2H2 zinc-finger motifs are capable of binding to a wide range of DNA sequences, including the HIV-1 LTR (Wu et al., 1995; Isalan et al., 2001).
We have demonstrated previously that one putative antiviral mechanism of OTK18 involves direct suppression of the

LTR (Carlson et al., 2004a). Mutational analyses revealed
that the suppressive activity of OTK18 lies within aa 26–89.
This region has homology to a family of zinc-finger proteins
containing the Krüppel-associated box (KRAB) motif, a repression domain encoded by numerous transcription factors.
Pengue et al. (1995) found that the KRAB domain fused to
HIV-1 Tat was able to repress basal HIV-1 promoter activity in HeLa cells. This finding was supported further by the
demonstration that a KRAB-containing tetracycline-binding
protein can suppress HIV-1 replication through randomly
integrated tetracycline-response elements within the HIV-1
genomic sequence (Herchenroder et al., 1999). In addition,
Reynolds et al. (2003) reported that a genetically engineered
KRAB domain containing a C2H2-type zinc-finger protein
could suppress Tat-mediated HIV-1 LTR activity, thereby
making it an attractive candidate for antiretroviral therapy
(Reynolds et al., 2003). In this context, OTK18 is the first
KRAB-containing C2H2 zinc-finger protein expressed endogenously in macrophages that has antiviral activity. Interestingly, OTK18 is expressed specifically in the cytosol of
brain mononuclear phagocytes in severe HIV-1 encephalitis
and may serve as a ‘surrogate’ marker for HIV-1-associated
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dementia (Carlson et al., 2004b). Elucidation of OTK18binding sequences within the HIV-1 LTR is critical for the
molecular characterization of OTK18 antiviral activity.
In this study, we employed all 27 LTR promoter linkerscanning mutants fused to the luciferase gene to screen for
potential OTK18 response elements in the LTR (–453/+18)
of the HXB2 clone (Zeichner et al., 1991). The linker-scanning mutants consecutively replaced 18 bp of wild-type sequence with an NdeI–XhoI–SalI(NXS) polylinker (CATATGCTCGAGGTCGAC) across the U3 and R regions.
Human embryonic kidney 293 cells (105 cells per well on
24-well plates; Fisher Scientific) were co-transfected with
the LTR-scanning mutant luciferase vectors (300 ng), Tat1–
72 expression vector (pSV2Tat72, 50 ng) (Subramani et al.,
1981), a Renilla luciferase reference construct (pTK-RL,
50 ng) and the OTK18 expression vector (pcDNA-OTK18,
1 μg) by using GenePorter (Gene Therapy Systems) as described previously (Carlson et al., 2004a). Forty-eight
hours after transfection, cells were collected and luciferase
activity was measured by using a luminometer (Berthold
Systems Inc.) using a Dual-Luciferase kit (Promega). As
shown in Table 1, we identified six regions (A3, A8, A10,
A12, B1 and B6, corresponding to –417/–400, –327/–310,
–291/–274, –255/–238, –237/–220 and –147/–130), which
were resistant to the OTK18-mediated gene suppression in
the presence of Tat. These codes correspond to the original
codes by Zeichner et al. (1991).
The binding of OTK18 to each of these six regions
was tested by a novel DNA–transcription factor ELISA,
which is about tenfold more sensitive than conventional
electromobility gel-shift analysis (EMSA). Development of
such a technique was necessary, as binding of OTK18 to
double-stranded oligonucleotides corresponding to the regions was too weak to be examined by conventional EMSA
(data not shown). For that purpose, we generated a baculovirus expressing 6xHis-Express-tagged full-length OTK18
by in-frame insertion of the full-length OTK18 gene into
the pBlueBacHis2A vector (Invitrogen) at the BamHI site.
The resultant vector (pBlueBacHis2A-OTK18) was inserted into Bac-N-Blue Autographa californica multiple
nucleopolyhedrovirus DNA by homologous recombination
according to the manufacturer’s protocol. Infection of Sf9
insect cells with the optimized titre of OTK18 baculovirus
resulted in expression of recombinant OTK18 at 84 h postinfection, detected as a 75 kDa protein (data not shown).
OTK18 protein was collected specifically from the nuclearextract fraction, which we used for subsequent experiments
as control nuclear extract.
The DNA–transcription factor ELISA method was
originally described by Reynolds et al. (2003) and is available commercially as the colorimetric ELISA TransAM kit
(Active Motif). To enhance the sensitivity of the original
protocol, we incorporated luminol-based conversion of hy-
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drogen peroxidase activity to chemiluminescence by using SuperSignal ELISA Pico chemiluminescent substrate
(Pierce) instead of conventional chromogenic development.
As shown in Figure 1, the colorimetric ELISA shows a statistically significant difference between a non-specific oligonucleotide (control) and the HIV-1 LTR oligonucleotide
A8 in the presence of OTK18-containing nuclear extract
from 0.5 to 5 μg input (Figure 1a), but the signal-to-noise
(S/N) ratio is 1.31–1.41 and Z' factors are –5.64 to 0.045.
In the case of our luminescence system, there is statistical significance between two groups from 0.5 to 5 μg input (Figure 1b), with an S/N ratio of 1.83–2.59 and Z′ factors of –0.88 to 0.85, which was calculated as described by
Zhang et al. (1999). As a higher S/N ratio and Z′ factor indicate suitability of the assay system, we conclude that our
luminescence system is superior to the colorimetric system, and we chose 2 μg nuclear extract for the following
experiment.
The OTK18-binding activity to each element and
its sensitivity to cold probe ranging from 1x to 100x was
tested (Figure 1c). The oligonucleotide pairs used for double-stranded DNA probes are A3 [biotin-(Nx100)-CCTTGATCTGTGGATCTA and TAGATCCACAGATCAAGG],
A8 [biotin-(Nx100)-TGGATGGTGCTACAAGCT and
[biotin-(Nx100)AGCTTGTAGCACCATCCA], A10
GAAGTTAGAAGAAGCCAA and TTGGCTTCTTCTAACTTC], A12 [biotin-(Nx100)-CTTGTTACACCCTGTGAG
and CTCACAGGGTGTAACAAG], B1 [biotin-(Nx100)CCTGCATGGAATGGATGA and TCATCCATTCCATGCAGG], B6 [biotin-(Nx100)-TCCGGAGTACTTCAAGAA and TTCTTGAAGTACTCCGG] and EBS
[biotin-(Nx100)-CATCCGGAG and CTCCGGATG].
OTK18 binding was specific, as significant binding occurred only in the presence of OTK18-infected cell lysate
and not in the presence of lysis buffer alone or uninfected
cell lysate (Figure 1d). Whilst regions A3, A8 and B1 demonstrated significant binding to OTK18, none of them was
outcompeted significantly by cold probes in a dose-dependent manner (Figure 1d). Only the A12 and EBS elements
showed significant binding to OTK18, which was outcompeted by cold probes. The B1 element showed OTK18
binding, but was not outcompeted by cold probe, and B6,
which contains partial EBS sequence, had no binding activity. In addition, none of the binding was outcompeted by up
to 100-fold excess of single-stranded oligonucleotides corresponding to the binding sequence, suggesting its specificity to double-stranded DNA (data not shown). These data
indicate that the A12 and EBS elements are potential specific OTK18-binding sites on the HIV-1 LTR.
The EBS is known to be an important response element for the cooperative interaction of Ets-1 with the upstream stimulatory factor (USF)-1 in HIV-1 enhancer activity (Sieweke et al., 1998). As the B6 region does not cover
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Table 1. Suppression of LTR linker-scanning mutants by OTK18

EBS completely, we created an HXB2-derived LTR luciferase vector lacking EBS (–150/–139) (pLTRΔEBS-Luc)
with a modified QuikChange II site-directed mutagenesis
kit (Stratagene) using oligonucleotide pairs and tested its
promoter activity in the presence/absence of HIV-1 Tat and
OTK18 in 293 cells (Figure 2). Unexpectedly, pLTRΔEBSLuc showed enhanced luciferase activity in the presence of
Tat and OTK18 (second column) compared with Tat alone
(first column). Tat-activated luciferase activity of the original LTR-Luc, on the other hand, was suppressed significantly by OTK18 (Figure 2b). This suggested that EBS is a
critical element for the OTK18-mediated LTR suppression
and that OTK18 has a dual regulatory function in the HIV-1
LTR, dependent on specific binding regions (see below). As
the proximal promoter region between nucleosomes nuc0
and nuc1, where EBS is located, has been established as a
critical regulatory region, EBS is an important site for the
suppressive effect of OTK18. All of the above data indicate
that EBS (–150/–139) is the primary OTK18 response element on the HIV-1 LTR.
We have shown previously that the transcriptional factor OTK18 suppresses both HIV-1 Tat-mediated LTR activation in vitro and HIV-1 replication in human monocyte-

derived macrophages (MDMs) (Carlson et al., 2004a).
However, the response element for OTK18 suppression
has not been determined. We have shown that OTK18 interacts with two distinct regions on the HIV-1 LTR, the
NRE and EBS regions, by using LTR-scanning mutants
and EMSA and through more defined subcloning/deletional
analyses. Multiple regions of the NRE have been reported
to downregulate HIV transcription (Garcia et al., 1987).
Specifically, NRE (–182/–153) contains a binding site for
the nuclear factors USF (Sawadogo et al., 1988), NFIL-6
(Tesmer et al., 1993) and human GATA-3 (Yang & Engel,
1993; Galio et al., 1999). Furthermore, NRE (–220/–160)
binds to nuclear matrix proteins and inhibits NF-κB activity (Hoover et al., 1996). However, no proteins have been
identified that bind to NRE (–255/–238). Thus, OTK18, to
the best of our knowledge, is the first cellular protein to be
shown to interact with this specific region of the NRE and
suppress the HIV-1 LTR.
A number of mutations were reported at this region
in LTRs derived from human genomic DNA of HIV-1-infected patients. Estable et al. (1996) reported LTR-proximal sequences from 42 HIV-1-infected cases ranging
from stage I to IV patients (World Health Organization
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Figure 1. DNA ELISA screening for binding of OTK18 to HIV-1 LTR regions. (a, b) Improved chemiluminescent method for DNA–
transcription factor ELISA. Sensitivity of two methods, conventional colorimetry (a) and chemiluminescence (b), was compared by
using varying amounts of OTK18 protein extracts bound to a negative-control oligonucleotide (empty bars) or a double-stranded
oligonucleotide corresponding to the A8 region of the HIV-1 LTR region (filled bars). Statistical analysis was performed by using
one-way ANOVA to compare binding of each amount of extract with the binding of the negative-control oligonucleotide for the corresponding amount of extract (*P<0.001; §P<0.05). (c) Six regions of the HIV-1 LTR (A3–B6 and EBS) were screened for specific
binding of the OTK18 protein. Binding was compared in the presence of lysis buffer alone (no lysate, filled bars), uninfected Sf9
cell lysate (uninfected lysate, shaded bars) or OTK18 baculovirus-infected lysate (OTK18 lysate, empty bars). Only the OTK18 lysate showed significant binding (*P<0.001 compared with no lysate or uninfected lysate). (d) Binding was tested in the presence
of no extract (–, empty bars), extract alone with no competing oligonucleotide (0x, filled bars), 1x excess of the corresponding
LTR oligonucleotide (checked bars), 5x excess oligonucleotide (diagonally hatched bars), 20x excess oligonucleotide (horizontally
hatched bars) or 100x oligonucleotide (shaded bars). Statistical analysis was performed by using one-way ANOVA to compare
binding of each oligonucleotide with no competitor present to the corresponding no-extract condition (#P<0.001). Statistical analysis was also performed by using one-way ANOVA to compare binding of the competition conditions with the no-competitor condition for the same oligonucleotide (†P<0.01; #P<0.001). NC, Negative control; RLU, relative luciferase units.

staging I–IV). Although they concluded that the Ets core
sequence (ATCCG) was highly conserved, 25 of a total
of 60 LTR sequences from the 42 cases were mutated in
the Ets-1 element. The Ets core sequence was highly conserved in non-B subtypes (De Arellano et al., 2005). We

have also examined the available LTR depository at the
Los Alamos HIV sequence database for LTRs of A, B, C
and D subtypes. The conservation of ETS core sequence
(ATCCG) was 19/19 (100 %, A), 45/48 (94 %, B), 73/74
(97 %, C) and (90 %, D).
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to characterize the expression of these OTK18 isoforms in
MDMs and their respective roles in HIV-1 replication and
LTR regulation.
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